Compare RVLV & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVLV | GALT |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 199.2M |
| IPO Year | 2018 | 2008 |
| Metric | RVLV | GALT |
|---|---|---|
| Price | $23.66 | $2.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $29.73 | $8.50 |
| AVG Volume (30 Days) | ★ 707.7K | 332.0K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.64 | ★ 36.84 |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $1,225,682,000.00 | N/A |
| Revenue This Year | $10.96 | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | $25.87 | ★ N/A |
| Revenue Growth | ★ 8.48 | N/A |
| 52 Week Low | $16.80 | $1.22 |
| 52 Week High | $31.68 | $7.13 |
| Indicator | RVLV | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 38.30 |
| Support Level | $20.18 | $2.07 |
| Resistance Level | $24.30 | $3.32 |
| Average True Range (ATR) | 0.90 | 0.20 |
| MACD | 0.21 | -0.03 |
| Stochastic Oscillator | 100.00 | 3.69 |
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.